Modus Therapeutics publishes interim report for the third quarter 2022

STOCKHOLM, SWEDEN - 22 November 2022: Modus Therapeutics Holding AB (” Modus Therapeutics”) hereby publishes an interim report for the third quarter 2022. The report is available as an attached document and on the company's website (www.modustx.com/investors/financial-reports.html). Below is a summary of the interim report.

The third quarter in figures

• The loss after tax amounted to TSEK 2 908 (4 441).
• The loss per share amounted to SEK 0,18 (0,30).
• The cash flow from current operations was negative in the amount of TSEK 2 760 (4 226).

The first 9-months in figures

• The loss after tax amounted to TSEK 8 964 (8 402).
• The loss per share amounted to SEK 0,56 (0,76).
• The cash flow from current operations was negative in the amount of TSEK 13 532 (7 691).

Important events during the quarter

• Modus Therapeutics concludes on bridge financing agreement from Karolinska Development.
• Modus Therapeutics announces first patient enrolled in clinical trial evaluating sevuparin in paediatric patients with severe malaria.
• Modus Therapeutics participated in Nordic Life Science days.
• Modus Therapeutics completes recruitment for Phase 1b LPS provocation study.

Important events after the end of the period

• Modus Therapeutics participated in BIO-EUROPE.

CEO John Öhd comments on the report in an interview with Jonathan Furelid.

Link to Interview: https://youtu.be/bNOAnoO3mi0

This information is such information that Modus Therapeutics Holding AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the contact person below, for publication on November 22nd, 2022.

For more information on Modus Therapeutics, please contact:

John Öhd, VD, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: john.ohd@modustx.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Phone: +46 11 32 30 732

Email: ca@skmg.se

About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects.  Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.